Trademark: 79266012
Word
LETYBO
Status
Registered
Status Code
700
Status Date
Tuesday, October 27, 2020
Serial Number
79266012
Registration Number
6181983
Registration Date
Tuesday, October 27, 2020
Mark Type
4
Filing Date
Thursday, June 13, 2019
Published for Opposition
Tuesday, August 11, 2020

Trademark Owner History
HUGEL INC. - Original Registrant

Classifications
5 Pharmaceutical preparations for the treatment of spasm; pharmaceutical preparations for treating dystonia; muscle relaxants; pharmaceutical products for skin care for animals; pharmaceutical preparations used in cosmetic surgery; pharmaceutical preparations containing botulinum toxin; botulinum toxin for medical use for use in the treatment of neuropathy pain; pharmaceutical preparations containing botulinum toxin for the treatment of wrinkles; pharmaceutical preparations containing botulinum toxin fragments for the treatment of wrinkles; pharmaceutical preparations for use in treating urogenital system diseases and conditions, namely, overactive bladder and urinary incontinence; bacterial toxins, namely, bacterial poisons; pharmaceutical preparations for digestive system; pharmacological preparations for skin care; pharmaceutical preparations for treating peripheral neurological diseases and disorders; pharmaceutical preparations for treating central neurological diseases and disorders; ophthalmic preparations for use in the treatment of blepharospasm and strabismus; medicated ointments for treating dermatological conditions; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis and cerebral palsy; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; chemical preparations for [ phamaceutical ] * pharmaceutical * purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; pharmaceutical agents for epidermis; drugs for medical purposes for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis and cerebral palsy; drugs for medical purposes for the treatment of sports injuries, namely, injured or torn skin, muscle, ligaments or bone; drugs for medical purposes for the treatment of tremors, namely, spasmodic smooth, striated or cardiac muscles; drugs for medical purposes for the treatment of pain, namely, smooth muscle pain, striated muscle pain, cardiac muscle pain, neuropathic pain, inflammatory pain, visceral pain, chronic pain, acute pain, traumatic injury pain, referred pain, growing pain, hunger pain, intractable pain, labour pain, organic pain, phantom limb pain, postprandial pain, psychogenic pain, back pain, post-stroke pain, cancer pain, nociceptive pain, headache pain, prostatic pain, and bladder pain; biological preparations for medical or veterinary purposes for the treatment of aesthetic dermatology, orthopaedics, arthritis and ophthalmology; cultures of microorganisms for medical or veterinary use; chemical reagents for medical or veterinary purposes; bacteriological preparations for medical and veterinary use; adjuvants for medical purposes; hyaluronic acid preparations for medical purposes; medicines for human purpose, namely, medicines for skin care; pharmaceutical preparations for the treatment of psychiatric diseases and disorders; pharmaceutical preparations for the treatment of orthopaedic disorders, namely, hip dislocation, spinal column deformation, curvature of the spine, namely, scoliosis, lordosis, cyphosis; pharmaceutical preparations for smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, tremors and pain; pharmaceutical preparations for the treatment of wrinkles; injectable dermal filler; medicines for dental purposes; preparation for the relief of pain; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations mainly based on hyaluronic acid for treatments, namely, injectable for intradermal and subcutaneous application for facial and body skin tightening and smoothing; botulinum toxin for medical use for use in the treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, headache, pain, spasm, dystonia, urogenital system diseases and conditions, skin disorders; therapeutic drugs and agents for use in the treatment of excessive sweating, excessive eye blinking, neuropathy pain, facial wrinkles, headache, pain, spasm, dystonia, urogenital system diseases and conditions, skin disorders
In statement Class 5, has been corrected per the F-note dated 4/11/2024.

Trademark Events
Sep 4, 2019
Assigned To Examiner
Aug 22, 2019
Sn Assigned For Sect 66a Appl From Ib
Aug 26, 2019
Limitation From Original Application Entered
Sep 4, 2019
New Application Office Supplied Data Entered
Sep 5, 2019
Non-Final Action Written
Sep 6, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Sep 10, 2019
Application Filing Receipt Mailed
Sep 16, 2019
Refusal Processed By Mpu
Sep 16, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Oct 5, 2019
Refusal Processed By Ib
Mar 12, 2020
Teas Response To Office Action Received
Mar 12, 2020
Teas Response To Office Action Received
Mar 12, 2020
Correspondence Received In Law Office
Mar 12, 2020
Teas/Email Correspondence Entered
Mar 26, 2020
Approved For Pub - Principal Register
Apr 22, 2020
Notification Of Notice Of Publication E-Mailed
May 12, 2020
Published For Opposition
May 12, 2020
Official Gazette Publication Confirmation E-Mailed
Jul 6, 2020
Withdrawn From Issue - Managing Attorney Request
Jul 22, 2020
Notification Of Notice Of Publication E-Mailed
Jul 22, 2020
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jul 22, 2020
Notification Of Possible Opposition Sent To Ib
Aug 7, 2020
Notification Processed By Ib
Aug 11, 2020
Published For Opposition
Aug 11, 2020
Official Gazette Publication Confirmation E-Mailed
Oct 27, 2020
Registered-Principal Register
Feb 6, 2021
Final Disposition Processed
Jan 27, 2021
Final Disposition Notice Created, To Be Sent To Ib
Mar 17, 2024
Correction Transaction Received From Ib
Apr 11, 2024
Correction Under Section 7 - Processed
Apr 12, 2024
Correction From Ib Entered - No Review Required
May 21, 2024
Notice Of Updated Registration Confirmation Emailed
Feb 6, 2021
Final Disposition Notice Sent To Ib
Feb 27, 2021
New Representative At Ib Received
Mar 7, 2021
Final Decision Transaction Processed By Ib

Trademark Alertz updated from USPTO on 2030-01-24